Literature DB >> 2615532

Combination of pipemidic acid, colistin sodium methanesulfonate and nystatin may be less effective than nystatin alone for prevention of infection during chemotherapy-induced granulocytopenia in acute leukemia.

K Sampi1, M Sakurai, R Kumai, N Maseki, Y Kaneko, M Hattori.   

Abstract

Pipemidic acid (PPA) and colistin sodium methanesulfonate (CLM) may selectively suppress aerobic gram-negative bacilli. Twenty-nine patients with acute leukemia were randomized after each course of consolidation chemotherapy to receive a single agent of nystatin (NYS) (34 courses) versus a combination of NYS, PPA and CLM (36 courses). The duration of fever over 39 degrees C was longer with the three drug combination (4.6 +/- 5.1 days) than with NYS alone (1.8 +/- 1.8 days) (P less than 0.01). Four cases of pneumonia occurred and four patients including one having pneumonia died of infection with the three drug combination, while no pneumonia or death occurred with NYS alone (P = 0.06 and P = 0.06, respectively). The combination of NYS, PPA and CLM may be less effective than NYS alone for the prevention of infection in acute leukemia patients with chemotherapy-associated granulocytopenia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615532     DOI: 10.1007/bf02985164

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  16 in total

1.  Determination of the colonization resistance of the digestive tract of individual mice.

Authors:  D van der Waaij; J M Berghuis
Journal:  J Hyg (Lond)       Date:  1974-06

2.  Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia.

Authors:  A S Levine; S E Siegel; A D Schreiber; J Hauser; H Preisler; I M Goldstein; F Seidler; R Simon; S Perry; J E Bennett; E S Henderson
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

3.  Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.

Authors:  H D Preisler; A Raza; A Early; J Kirshner; M Brecher; A Freeman; Y Rustum; N Azarnia; R Priore; A Sandberg
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

Review 4.  Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.

Authors:  R J Mayer
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

5.  Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.

Authors:  D T Sleijfer; N H Mulder; H G de Vries-Hospers; V Fidler; H O Nieweg; D van der Waaij; H K van Saene
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

6.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

7.  Colonization resistance of the digestive tract in conventional and antibiotic-treated mice.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1971-09

8.  Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.

Authors:  M S Tallman; F R Appelbaum; D Amos; R S Goldberg; R B Livingston; J Mortimer; P L Weiden; E D Thomas
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

9.  High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study.

Authors:  S N Wolff; J Marion; R S Stein; J M Flexner; H M Lazarus; T R Spitzer; G L Phillips; R H Herzig; G P Herzig
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

10.  A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia.

Authors:  J C Wade; S C Schimpff; M T Hargadon; C L Fortner; V M Young; P H Wiernik
Journal:  N Engl J Med       Date:  1981-04-30       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.